Patent US4610869A successfully refreshed from Google Patents.
US4610869A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for in vivo testing of biological response modifiers including monoclonal antibodies
Assignee: Primedica Worcester Inc
•
Filing: 1983-10-24
•
Granted: 1986-09-09
•
Expires: 2003-10-24
Abstract
Abstract In vivo method for determining the ability of biological response modifiers, including monoclonal antibodies, to interact with tumor tissue. A fresh, surgical tumor tissue specimen is implanted under the renal capsule of a host organism. A biological response modifier is administered to the host organism. The degree of interaction between the biological response modifier and the tumor tissue is determined. This method is particularly suitable for determining the ability of a biological response modifier to interact with fresh, surgically-obtained tumor tissue when using an immunocompetent host in an assay of short duration.
Inventors
- 👤 Arthur E. Bogden
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 12:22
CPC Classifications
A; A61; A61K; A61K49/00; A61K49/0004; A61K49/0008; Y; Y10; Y10S; Y10S436/00; Y10S436/811
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
57 words
A method for determining the ability of a biological response modifier to interact with tissue cells comprising: a. implanting fresh, surgically-obtained tumor tissue under the renal capsule of a host organism; b. administering said biological response modifier to said host organism; and c. determining the degree of interaction between said biological response modifier and said tumor tissue.
Claim 2
Independent Claim
57 words
A method for determining the ability of a biological response modifier to interact with tissue cells comprising: a. implanting fresh, surgically-obtained tumor tissue under the renal capsule of a host organism; b. administering said biological response modifier to said host organism; and c. determining the degree of interaction between said biological response modifier and said tumor tissue.
Claim 3
Dependent Claim
14 words
The method of claim 1 wherein said biological response modifier is a monoclonal antibody.
Claim 4
Dependent Claim
14 words
The method of claim 1 wherein said biological response modifier is a polyclonal antibody.
Claim 5
Dependent Claim
16 words
The method of claim 1 wherein said biological response modifier is a vitamin derivative or precursor.
Claim 6
Dependent Claim
13 words
The method of claim 1 wherein said biological response modifier is an interferon.
Claim 7
Dependent Claim
14 words
The method of claim 1 wherein said biological response modifier is a naturally-occurring substance.
Claim 8
Dependent Claim
11 words
The method of claim 6 wherein said naturally-occurring substance is interleukin.
Claim 9
Dependent Claim
11 words
The method of claim 1 wherein the host is a rodent.
Claim 10
Dependent Claim
10 words
The method of claim 8 wherein the host is immunocompetent.
Claim 11
Dependent Claim
12 words
The method of claim 8 wherein the host posesses no thymus gland.
Claim 12
Dependent Claim
12 words
The method of claim 1 wherein said biological response modifier is radiolabelled.
Claim 13
Dependent Claim
13 words
The method of claim 11 wherein said determining is accomplished by radioactive imaging.
Claim 14
Dependent Claim
19 words
The method of claim 12 wherein said imaging is accomplished while said tumor tissue is located within said host.
Claim 15
Dependent Claim
19 words
The method of claim 12 wherein said imaging is accomplished after said tumor tissue is removed from said host.
Claim 16
Dependent Claim
16 words
The method of claim 1 wherein said biological response modifier is labelled with a fluorescent substance.
Claim 17
Dependent Claim
13 words
The method of claim 15 wherein said determining is conducted by fluorescent imaging.
Claim 18
Dependent Claim
14 words
The method of claim 1 wherein said determining is conducted by a chemical assay.
Claim 19
Independent Claim
78 words
A method for screening a plurality of biological response modifiers to identify the biological response modifiers best suited for treatment of a tumor comprising: a. implanting pieces of fresh tumor tissue of the same type, surgically-obtained from a patient, under the renal capsule of a plurality of host organisms; b. administering a different biological response modifier to each host organism; and c. determining which biological response modifier exhibits the greatest response to or interaction with the tumor tissue.
Claim 20
Independent Claim
78 words
A method for screening a plurality of biological response modifiers to identify the biological response modifiers best suited for treatment of a tumor comprising: a. implanting pieces of fresh tumor tissue of the same type, surgically-obtained from a patient, under the renal capsule of a plurality of host organisms; b. administering a different biological response modifier to each host organism; and c. determining which biological response modifier exhibits the greatest response to or interaction with the tumor tissue.
Claim 21
Independent Claim
90 words
A method for predicting the clinical usefulness of a biological response modifier comprising: a. surgically obtaining, from a plurality of patients, fresh pieces of tumor tissue of the same type; b. implanting, under the renal capsule of a plurality of host organisms, said pieces of fresh tumor tissue; c. administering the same biological response modifier to each of the plurality of host organisms; and d. determining which host organism exhibits the greatest response to said biological response modifier or greatest interaction between said biological response modifier and said tumor tissue.
Claim 22
Independent Claim
90 words
A method for predicting the clinical usefulness of a biological response modifier comprising: a. surgically obtaining, from a plurality of patients, fresh pieces of tumor tissue of the same type; b. implanting, under the renal capsule of a plurality of host organisms, said pieces of fresh tumor tissue; c. administering the same biological response modifier to each of the plurality of host organisms; and d. determining which host organism exhibits the greatest response to said biological response modifier or greatest interaction between said biological response modifier and said tumor tissue.
Claim 23
Independent Claim
57 words
A method for determining the ability of a biological response modifier to interact with tissue cells comprising: a. administering said biological response modifier to said host organism; b. implanting fresh, surgically-obtained tumor tissue under the renal capsule of a host organism; and c. determining the degree of interaction between said biological response modifier and said tumor tissue.
Claim 24
Independent Claim
57 words
A method for determining the ability of a biological response modifier to interact with tissue cells comprising: a. administering said biological response modifier to said host organism; b. implanting fresh, surgically-obtained tumor tissue under the renal capsule of a host organism; and c. determining the degree of interaction between said biological response modifier and said tumor tissue.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-09-08 | 1990-03-10 | 1990-09-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-09-08 | 1994-03-10 | 1994-09-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-09-08 | 1998-03-10 | 1998-09-09 | $7700.00 | Window Closed / Lapsed |